Comparison of the Efficacy and Safety of Low-molecular-weight Heparin and Dabigatran Ester in Anticoagulant Treatment of Non Valvular Atrial Fibrillation Patients
Objective:To compare the efficacy and safety of Low-molecular-weight Heparin and Dabigatran Ester in anticoagulant treatment of non valvular atrial fibrillation patients.Method:A total of 60 patients with non valvular atrial fibrillation patients treated in Chongqing Youyang County People's Hospital from January to December 2022 were selected.After admission,they were divided into groups by odd-even number method.30 patients with odd number were included in the control group and 30 patients with even number were included in the observation group.Observation group was given anticoagulation therapy with Low-molecular-weight Heparin,control group was given anticoagulation therapy with Dabigatran Ester.Thrombin time(TT),activated partial thromboplastin time(APTT),D-dimer(D-D),incidence of drug-related adverse reactions,incidence of adverse events during treatment,and overall treatment response rate were compared between the two groups.Result:Before treatment,there were no statistically significant difference in TT,APTT and D-D levels between the two groups(P>0.05).After treatment,TT and APTT in the observation group were longer than those in the control group,D-D level was lower than that in the control group,the incidence of drug-related adverse reactions was lower than that in the control group,the incidence of adverse events during treatment was lower than that in the control group,and the total effective rate was higher,the differences were statistically significant(P<0.05).Conclusion:The efficacy and safety of anticoagulation therapy with Low-molecular-weight Heparin in non valvular atrial fibrillation patients are higher than those with Dabigatran Ester.
国家科技期刊平台
NSTL
万方数据
